Immunovant, Inc. (IMVT)

NMS – Real vaqt narxi. Valyuta: USD

41.90

+0.97 (2.37%)

Bozor ochiq: Aug 12, 2026, 12:38 PM EDT

40.93

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:40 PM EDT

06.08.2026

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

06.08.2026

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.

06.08.2026

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

06.08.2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Immunovant, Inc. (IMVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 Earnings Call Highlights

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 Earnings Call Highlights

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Search stocks

Immunovant, Inc. (IMVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 Earnings Call Highlights

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 Earnings Call Highlights

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026